- A new oral antiviral drug candidate, GHP-88310, shows promise in treating three major viral threats, including measles, parainfluenza, and henipaviruses.
- The once-daily pill demonstrated potent activity against these viruses in preclinical trials, reducing viral loads and improving survival rates.
- Orthoparamyxoviruses cause hundreds of thousands of deaths worldwide each year, with measles alone responsible for over 100,000 fatalities in 2023.
- The lack of effective treatments for these viruses highlights the urgent need for broad-spectrum antivirals, which can target multiple viruses at once.
- GHP-88310 marks a significant step toward developing a therapy that can combat some of the world’s most dangerous respiratory and systemic viral infections.
Every year, orthoparamyxoviruses are responsible for hundreds of thousands of deaths worldwide, with measles alone causing over 100,000 fatalities in 2023, predominantly among unvaccinated children, according to the World Health Organization. Now, a breakthrough antiviral candidate developed at Georgia State University has demonstrated potent activity against this entire family of viruses—including human parainfluenzaviruses that cause croup, the measles virus, and emerging henipaviruses like Nipah and Hendra, which have mortality rates exceeding 75% in some outbreaks. In preclinical trials, the once-daily oral drug GHP-88310 significantly reduced viral loads and improved survival rates in both rodent and non-rodent animal models, marking a pivotal step toward a broad-spectrum therapy for some of the world’s most dangerous respiratory and systemic viral infections.
The Urgent Need for Broad-Spectrum Antivirals
Despite advances in vaccination, orthoparamyxoviruses remain a persistent global health threat due to incomplete vaccine coverage, waning immunity, and the lack of effective treatments once infection occurs. Measles continues to circulate in under-immunized communities, while human parainfluenzaviruses (HPIVs) are a leading cause of croup and lower respiratory tract infections in children. Meanwhile, henipaviruses, zoonotic pathogens primarily transmitted from bats, have caused sporadic but deadly outbreaks in Southeast Asia and Australia, with no approved antivirals for human use. The development of GHP-88310, detailed in a recent Science Advances paper, addresses a critical gap in antiviral medicine by targeting a conserved viral mechanism across multiple species within the orthoparamyxovirus family, offering a potential unified therapeutic strategy.
GHP-88310: Mechanism and Preclinical Success
GHP-88310 works by inhibiting the viral RNA-dependent RNA polymerase, a key enzyme required for replication across orthoparamyxoviruses. This mechanism allows the drug to remain effective against diverse members of the virus family, even those with high genetic variability. In studies conducted by the Center for Translational Antiviral Research at Georgia State University, the compound demonstrated robust antiviral activity in ferrets infected with parainfluenza virus and in African green monkeys exposed to measles virus. Treated animals showed faster viral clearance, reduced clinical symptoms, and no significant toxicity, supporting its potential for safe human use. Notably, the drug was effective both as a treatment and when administered prophylactically, suggesting possible use in outbreak containment and high-risk exposure scenarios.
Scientific Innovation and Drug Development Pipeline
The development of GHP-88310 represents a shift from pathogen-specific antivirals to a pan-orthoparamyxovirus approach, leveraging structural insights into conserved viral proteins. Researchers used structure-based drug design and high-throughput screening to identify lead compounds, optimizing GHP-88310 for oral bioavailability, metabolic stability, and blood-brain barrier penetration—critical for treating neurotropic viruses like Nipah. Unlike existing antivirals such as ribavirin, which has limited efficacy and significant side effects, GHP-88310 targets a more specific viral function, reducing the risk of host toxicity. The compound’s success in non-rodent models, particularly non-human primates, increases confidence in its translatability to human clinical trials, which are expected to begin within the next 18 months.
Global Health and Pandemic Preparedness Implications
If proven effective in humans, GHP-88310 could transform the management of multiple viral diseases, particularly in low-resource settings where access to vaccines and intensive care is limited. The oral formulation enables decentralized treatment, potentially reducing hospitalization rates for croup and measles complications. More importantly, the drug could serve as a first-line countermeasure against emerging henipaviruses, which are classified as priority pathogens by the WHO due to their pandemic potential. In outbreak zones, a readily deployable pill could bridge the gap until vaccines are developed or distributed, significantly improving response timelines and saving lives during spillover events from animal reservoirs.
Expert Perspectives
Dr. Richard Kuhn, a virologist at Purdue University not involved in the study, called the findings “a significant leap forward in antiviral development,” noting that “targeting conserved viral machinery across multiple pathogens is the future of pandemic preparedness.” However, some experts urge caution. Dr. Angela Rasmussen of the University of Saskatchewan emphasized that while animal data are promising, “human immune responses and viral dynamics can differ substantially, and we must ensure safety and efficacy through rigorous clinical testing.” The balance between optimism and scientific prudence underscores the importance of phased trials and real-world monitoring.
As researchers prepare for human trials, key questions remain: How will GHP-88310 perform in immunocompromised patients? Can it be used in pediatric populations, where many of these viruses hit hardest? And will resistance emerge with prolonged use? Ongoing studies are also exploring combination therapies with monoclonal antibodies and vaccines to enhance protection. With global health agencies increasingly focused on cross-cutting medical countermeasures, GHP-88310 exemplifies the shift toward agile, broad-spectrum solutions capable of meeting both current and future viral threats.
Source: MedicalXpress